AZD 8165Alternative Names: AZD8165
Latest Information Update: 04 Feb 2014
At a glance
- Originator AstraZeneca
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 01 Sep 2010 Discontinued - Phase-I for Thrombosis in USA (PO)
- 01 Jun 2010 Phase-I clinical trials in Thrombosis in USA (PO)